ConductScience.org, home

Paper36724239

Additive efficacy of a bispecific anti-TNF/IL-6 nanobody compound in translational models of rheumatoid arthritis.

Biesemann N and 15 others. Sci Transl Med, 2023. Cited by 66 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Additive efficacy of a bispecific anti-TNF/IL-6 nanobody compound in translational models of rheumatoid arthritis. Papers, record 36724239. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36724239

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Additive efficacy of a bispecific anti-TNF/IL-6 nanobody compound in translational models of rheumatoid arthritis.
PubMed
Journal
Sci Transl Med
PubMed
Year
2023
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
66
iCite
Relative citation ratio, by iCite
6.78
iCite
Revised in PubMed
2023-04-17
PubMed

Authors16

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Biesemann NNadinehttps://orcid.org/0000-0002-3611-9703
2Margerie DDanielhttps://orcid.org/0000-0003-0598-8866
3Asbrand CChristianhttps://orcid.org/0000-0003-3141-7127
4Rehberg MMarkushttps://orcid.org/0000-0003-0223-0398
5Savova VVirginiahttps://orcid.org/0000-0002-5387-4161
6Agueusop IInoncent
7Klemmer DDaniel
8Ding-Pfennigdorff DDanpinghttps://orcid.org/0000-0002-0227-1168
9Schwahn UUwehttps://orcid.org/0000-0001-9183-3830
10Dudek MMarkushttps://orcid.org/0000-0003-1447-1308
11Heyninck KKarenhttps://orcid.org/0000-0002-4068-1344
12De Tavernier EEvelynhttps://orcid.org/0000-0002-1903-3027
13Cornelis SSigridhttps://orcid.org/0000-0001-5433-4151
14Kohlmann MMarkus
15Nestle FOFrank Ohttps://orcid.org/0000-0003-1033-5309
16Herrmann MMatthiashttps://orcid.org/0000-0002-0736-6668

Source PubMed

Download CSV of authors

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Arthritis, ExperimentalMajor topic
Arthritis, RheumatoidMajor topic
SynoviocytesMajor topic
Animals
Humans
Mice
Cells, Cultured
Fibroblasts
Synovial Membrane
Tumor Necrosis Factor Inhibitors
Tumor Necrosis Factor-alpha
Interleukin-6

Source PubMed

Download CSV of topics

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment in36894778Nanobody targets TNF and IL-6 for additive efficacy.https://conductscience.org/library/papers/36894778

Source PubMed

Download CSV of comments and corrections

Cited by47

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 66 citations.

PMIDTitleJournalYearIn PapersSource
42890560Engineering Tripterygium wilfordii-derived exosome-like nanoparticles for targeted therapy in rheumatoid arthritis.Extracell Vesicles Circ Nucl Acids2026https://conductscience.org/library/papers/42890560PubMed
42865714Sanguinarine ameliorates rheumatoid arthritis by activating the Hippo-YAP/TAZ pathway to induce apoptosis and suppress inflammation in fibroblast-like synoviocytes.Front Pharmacol2026https://conductscience.org/library/papers/42865714PubMed
42798472Combination of Chenpi and Banxia alleviates synovial inflammation in a rat model of rheumatoid arthritis by targeting the JNK/AP-1 signaling pathway.Front Immunol2026https://conductscience.org/library/papers/42798472PubMed
42620704Transcending aging: disease specificity, assessment challenges, and management strategies for rheumatoid arthritis-related sarcopenia.Front Med (Lausanne)2026https://conductscience.org/library/papers/42620704PubMed
42312209Stress-induced IL-6 regulation in pediatric bone growth disorders: current insights and therapeutic strategies.Front Endocrinol (Lausanne)2026https://conductscience.org/library/papers/42312209PubMed
42080357A Nanobody-LNP Platform for Targeting and Relicensing Dendritic Cells for Potent Cancer Immunotherapy.Adv Sci (Weinh)2026https://conductscience.org/library/papers/42080357PubMed
41978838Kadsua coccinea Extract Alleviates Rheumatoid Arthritis via TNF-α Suppression and Gut Microbiota Modulation.J Inflamm Res2026https://conductscience.org/library/papers/41978838PubMed
41972141Mechanisms of inflammation in premature ovarian insufficiency and advances in therapeutic studies.Front Immunol2026https://conductscience.org/library/papers/41972141PubMed
41832600Microglia-independent rAAV-induced inflammation causes persistent ocular immune dysregulation rescued by S1P receptor modulation.Mol Ther2026https://conductscience.org/library/papers/41832600PubMed
41752950Microvascular Genesis of Diseases: From Hypothesis to Theory.Life (Basel)2026https://conductscience.org/library/papers/41752950PubMed
41752211A Study on the Treatment of Rheumatoid Arthritis Using a Novel GelMA-HAMA Dual-Network Hydrogel Microneedle Loaded with MTX-NCs in Combination with Adalimumab.Int J Mol Sci2026https://conductscience.org/library/papers/41752211PubMed
41619129Emerging Therapeutics in Rheumatoid Arthritis.Curr Rheumatol Rep2026https://conductscience.org/library/papers/41619129PubMed
41595435Transcriptome Profiling of the Anterior Cingulate Cortex in a CFA-Induced Inflammatory Pain Model Identifies ECM-Related Genes in a Model of Rheumatoid Arthritis.Genes (Basel)2025https://conductscience.org/library/papers/41595435PubMed
41524227Antibody-Empowered Nanomedicine for Precise Biomedical Applications.Adv Sci (Weinh)2026https://conductscience.org/library/papers/41524227PubMed
41153712Effects of Janus Kinase Inhibitors on Rheumatoid Arthritis Pain: Clinical Evidence and Mechanistic Pathways.Biomedicines2025https://conductscience.org/library/papers/41153712PubMed
40988741Safety of Sarilumab in the treatment of rheumatoid arthritis: a real-world study based on the FAERS database.Front Med (Lausanne)2025https://conductscience.org/library/papers/40988741PubMed
40932933Critical signaling pathways in osteoclast differentiation and bone resorption: mechanisms and therapeutic implications for periprosthetic osteolysis.Front Cell Dev Biol2025https://conductscience.org/library/papers/40932933PubMed
40809131Building virtual patients using simulation-based inference.Front Syst Biol2024https://conductscience.org/library/papers/40809131PubMed
40707975Targeting rheumatoid arthritis: a molecular perspective on biologic therapies and clinical progress.J Biol Eng2025https://conductscience.org/library/papers/40707975PubMed
40662067Integrating clinical features, inflammatory markers, and immune profiles: a Yunke-based nomogram model for rheumatoid arthritis prognosis.Front Med (Lausanne)2025https://conductscience.org/library/papers/40662067PubMed

See all 47 cited byDownload CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
IL6R3570PubTator's text mininghttps://conductscience.org/library/genes/3570NCBI Gene
TNF7124PubTator's text mininghttps://conductscience.org/library/genes/7124NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36724239

GET https://conductscience.org/api/papers/v1/36724239/cited_by?page=2